Sign in

You're signed outSign in or to get full access.

Hao

Research Analyst at Wells Fargo

Hao's questions to Kymera Therapeutics (KYMR) leadership

Question · Q4 2025

Hao asked about the timing and expected data or events for Kymera's next potential oral immunology program.

Answer

Nello Mainolfi, Founder, President, and CEO, clarified that Kymera plans to disclose at least one novel program, most likely an immunology program, in the second half of the year.

Ask follow-up questions

Fintool

Fintool can predict Kymera Therapeutics logo KYMR's earnings beat/miss a week before the call